<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The major gap junction protein expressed in the heart, connexin43 (Cx43), is highly remodeled in the diseased heart </plain></SENT>
<SENT sid="1" pm="."><plain>Usually, Cx43 is down-regulated and heterogeneously redistributed to the lateral sides of cardiomyocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Reverse remodeling of the impaired Cx43 expression could restore <z:mpath ids='MPATH_458'>normal</z:mpath> cardiac function and normalize electrical stability </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, the reduced and <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> Cx43 expression in the heart will be addressed in hypertrophic, dilated and ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> together with its functional consequences of conduction velocity slowing, dispersed impulse conduction, its interaction with <z:mp ids='MP_0003045'>fibrosis</z:mp> and propensity to generate <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Finally, different therapies are discussed </plain></SENT>
<SENT sid="5" pm="."><plain>Treatments aimed to improve the Cx43 expression levels show new potentially anti-arrhythmic therapies during <z:hpo ids='HP_0001635'>heart failure</z:hpo>, but those in the context of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> can be anti-arrhythmogenic at the cost of larger <z:mpath ids='MPATH_124'>infarct</z:mpath> sizes </plain></SENT>
<SENT sid="6" pm="."><plain>This article is part of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics </plain></SENT>
</text></document>